<DOC>
	<DOCNO>NCT00856973</DOCNO>
	<brief_summary>A multi center , randomize study evaluate efficacy safety eszopiclone compare placebo child ( 6-11 year age , inclusive ) adolescent ( 12-17 year age , inclusive ) attention deficit/hyperactivity disorder ( ADHD ) associate insomnia .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Study Drug ( Eszopiclone ) Children Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia</brief_title>
	<detailed_description>This multi center , randomize , double blind , placebo control , fix dose study eszopiclone pediatric subject 6-17 year age , inclusive , ADHD associate insomnia . Subjects randomize approximately 1:1:1 either low dose oral eszopiclone ( 1 mg child age 6-11 year , 2 mg adolescent age 12-17 year ) , high dose oral eszopiclone ( 2 mg child age 6-11 year , 3 mg adolescent age 12-17 year ) placebo . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Subject male female 6 17 year age , inclusive , time consent . Subject must diagnosis ADHD define DSMIV criterion Subject must document ADHD associate insomnia , define subject subject 's parent/legal guardian report repeat difficulty sleep initiation ( sleep latency &gt; 30 minute ) consolidation , ( wake time sleep onset &gt; 45 minute ) despite adequate age appropriate time opportunity sleep . Subject 's Baseline PSG must reveal either &gt; 30 minute latency persistent sleep ( LPS ) &gt; 45 minute wake sleep onset ( WASO ) . Subject subject 's parent/legal guardian report daytime functional impairment result sleep problem . Subject subject 's parent/legal guardian report attempted fail behavioral intervention sleep problem , include regular bedtime rise time Subject 's sleep disturbance must attributable either direct physiologic effect drug abuse misuse prescribe medication whether use intend illicit manner . ( Female subject ≥8 year age must negative serum pregnancy test ) Subject must general good health Subject must able swallow tablet . If subject currently take medication ADHD , must stable dose regimen minimum 1 month prior time consent Subject weight &lt; 10th percentile age gender Subject clinically significant unstable medical illness/abnormality chronic disease . Subject documented history Bipolar I II Disorder , major depression , conduct disorder , generalize anxiety disorder history psychosis . Subject periodic limb movement &gt; 5 time per hour , demonstrate Baseline PSG . Subject sleep disorder breathing , demonstrate Baseline PSG . Subject another primary sleep disorder , secondary sleep disorder , know suspect medical psychiatric condition affect may affect sleep Subject history circadian rhythm disorder travel across ≥3 time zone study . Subject organic brain disease , history febrile seizure . Subject , opinion investigator , suicidal homicidal risk . Female subject pregnant lactating planning become pregnant . Subject take psychotropic medication without appropriate washout period ( ≥5 halflives ) prior randomization . Subject history severe allergies 1 class medication multiple adverse drug reaction . Subject history allergic reaction know suspected sensitivity racemic zopiclone , eszopiclone , substance contain formulation . Subject history alcohol substance abuse within 3 month study participation .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hypnotic</keyword>
	<keyword>Eszopiclone</keyword>
	<keyword>Attention Deficit/Hyperactivity Disorder</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Children</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Polysomnography</keyword>
	<keyword>Actigraphy</keyword>
</DOC>